Waiblingen, Germany / Shanghai, China – Shanghai Pharmaceuticals and Syntegon have signed an agreement to build a laboratory for continuous manufacturing technology in China. The cooperation will promote the application of this new technology, shorten development cycles of new drugs, reduce the cost of drug development, continuously improve the accessibility of new (especially orphan) drugs in China, and create more value for patients.
A “co-laboratory” cooperation
Zeng Chuiyu, Deputy Director of Shanghai Pharmaceutical Manufacturing Management Center and Director of Technology Innovation Center, said, “As a large pharmaceutical industry group listed in Shanghai and Hong Kong, Shanghai Pharmaceuticals has always been driven by technology and innovation, dedicated to solving clinical needs, and guided by quality, cost-performace, intelligent manufacturing, and green development to continuously optimize production layout and promote manufacturing excellence.”
Shanghai Pharmaceuticals and Syntegon will use their respective resources in this in-depth “co-laboratory” cooperation to create a domestic benchmark for continuous manufacturing, improve production efficiency, and help innovation development.
Fostering innovation in the pharmaceutical industry
Jerome Freissmuth, Vice President Pharma and International Sales of Syntegon, said, “This cooperation is of strategic importance to both parties. Syntegon will support Shanghai Pharmaceuticals in becoming a pioneer in continuous manufacturing in China's pharmaceutical industry. Syntegon has been investing heavily in China for 20 years to support the Chinese pharmaceutical industry with best-in-class technology – and this partnership will continue along this forward-looking path.”
Shanghai Pharmaceuticals has always been driven by technology and innovation: Zeng Chuiyu, Deputy Director of Shanghai Pharmaceutical Manufacturing Management Center and Director of Technology Innovation Center and Hu Shengli, Managing Director of Syntegon in China after signing the partnership.
Reproduction for press purposes free of charge with credit “Picture: Syntegon”
Hu Shengli, Managing Director of Syntegon in China, added, “Continuous manufacturing technology is an innovation in the pharmaceutical industry, which will shorten drug development cycles and bring new products to market quickly, while reducing the cost of drug development. China attaches great importance to the application and promotion of continuous manufacturing technology. Now, Syntegon and Shanghai Pharmaceuticals will establish the first laboratory in China, which will be dedicated to the promotion and application of the new technology in the field of innovative drugs and provide new ideas and accessible experimental platforms for the development of orphan drugs.”
About Syntegon Technology
Syntegon Technology is a leading global process and packaging technology provider. Formerly the packaging division of the Bosch Group, the company, headquartered in Waiblingen (Germany), has been offering complete solutions for the pharmaceutical and food industries for over 50 years. About 6,000 employees at 30 locations in more than 15 countries generated a total revenue of 1.3 billion euros in 2020. The portfolio of intelligent and sustainable technologies includes stand-alone machines, as well as complete systems and services. Fields of application in the pharmaceutical industry are the production, processing, filling, inspection and packaging of liquid and solid pharmaceuticals (e.g. syringes and capsules). In the food industry, the portfolio includes process technology for confectionery as well as packaging solutions for dry foods (e.g. bars, bakery products and coffee), frozen foods and dairy products.
About Shanghai Pharmaceutical Group
Shanghai Pharmaceutical Group Limited (Shanghai Pharmaceuticals) is a large pharmaceutical industry group listed on both the Shanghai and Hong Kong stock exchanges (HKSE stock code: 02607; SSE stock code: 601607). The company's main business covers pharmaceutical industry and commerce. With a turnover of RMB 191.9 billion in 2020, Shanghai Pharmaceuticals ranks among the Fortune 500 and the top 50 global pharmaceutical companies, is the second largest in China's pharmaceutical industry, and has been selected as a sample stock in the SSE 180 Index, the CSI 300 Index and the MSCI China Index. Shanghai Pharmaceuticals advocates the corporate core values of "innovation, integrity, cooperation, tolerance and responsibility". The company is committed to consistently improving the quality of people's healthy lives, striving to become a respected, industry-renowned leading brand-name pharmaceutical manufacturer and service provider in the health sector.